Shares of Fulgent Genetics Inc. (FLGT) surged 10.59% in pre-market trading on Friday, following the company's release of better-than-expected second-quarter 2025 financial results and an upward revision of its full-year guidance.

The genetic testing solutions provider reported adjusted earnings per share of $0.07 for Q2, significantly beating analyst estimates of a $0.18 loss per share. Revenue for the quarter came in at $81.803 million, surpassing the consensus estimate of $76.205 million and representing a 15.17% increase from the same period last year. The company's core revenue, a key metric for its operations, reached $81.7 million for the quarter.

Adding to the positive sentiment, Fulgent Genetics raised its 2025 core revenue guidance to $320 million, signaling strong confidence in its growth trajectory. However, the company also provided an outlook for a full-year non-GAAP loss per share of about $0.35. Despite this, investors appear to be focusing on the revenue growth and the company's ability to outperform expectations in a challenging market environment.